Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients

Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated acute myeloid leukemia (AML) patients. However, upfront resistance as well as relapse following initial response demonstrate the need for a deeper understanding of resistance mechanisms. In the present s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Pei, Shanshan, Pollyea, Daniel A., Gustafson, Annika, Stevens, Brett M., Minhajuddin, Mohammad, Fu, Rui, Riemondy, Kent A., Gillen, Austin E., Sheridan, Ryan M., Kim, Jihye, Costello, James C., Amaya, Maria L., Inguva, Anagha, Winters, Amanda, Ye, Haobin, Krug, Anna, Jones, Courtney L., Adane, Biniam, Khan, Nabilah, Ponder, Jessica, Schowinsky, Jeffrey, Abbott, Diana, Hammes, Andrew, Myers, Jason R., Ashton, John M., Nemkov, Travis, D’Alessandro, Angelo, Gutman, Jonathan A., Ramsey, Haley E., Savona, Michael R., Smith, Clayton A., Jordan, Craig T.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124979/
https://ncbi.nlm.nih.gov/pubmed/31974170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0710
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados